BioVersys Extends its Series C Round to CHF 32.6 Million with Investment from the AMR Action Fund
BioVersys AG announces extension of its Series C investment round to CHF 32.6 million as the AMR Action Fund makes its first European-based investmentBASEL, Switzerland, January 05, 2023 / B3C newswire / -- BioVersys AG, a privately held clinical stage, multi-asset Swiss pharmaceutical company focusing on research a...
Source: pharmiweb.com